Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
NASDAQ:CODX
Holding CODX?
Track your performance easily
Earnings Data
Report Date
Apr 08, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.34Last Year’s EPS
-$0.31Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -38.14%
|Next Earnings Date:Apr 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the development and international expansion of Co-Diagnostics' platforms and tests. However, the company faces challenges with decreased revenue, increased net losses, and uncertainty around FDA approvals.Company Guidance
During the Co-Diagnostics third quarter 2024 earnings call, the company provided guidance highlighting their strategic focus on expanding the Co-Dx PCR platform's global reach. Despite a decrease in total revenue to $0.6 million from $2.5 million in the previous year, Co-Diagnostics emphasized their ongoing efforts to secure FDA 510(k) clearance for over-the-counter use of their Co-Dx PCR Pro instrument and COVID-19 Test Cup. They are also preparing regulatory submissions in India, Africa, the Middle East, and Central and South America for various tests, including tuberculosis, respiratory multiplex, and HPV multiplex. The company reported a net loss of $9.7 million or $0.32 per share for the quarter, compared to a $6.0 million loss or $0.20 per share in the previous year, and ended the quarter with $37.7 million in cash and equivalents. Co-Diagnostics remains focused on managing their cash position and operational efficiencies to support their future commercial launch and long-term growth.Expansion and Development of Co-Dx PCR Platform
Continued development of the Co-Dx PCR platform with a focus on tuberculosis, respiratory multiplex, HPV multiplex, and Strep A tests. Active international expansion efforts in regions like Central and South America, Africa, and India.
International Trade Missions and Market Engagement
Participation in several trade shows and international trade missions to Asia, alongside Utah Governor and World Trade Center Utah executives, to strengthen partnerships and understand healthcare systems in Asian markets.
Progress on HPV Multiplex Test
Completion of chemistry optimization for the Co-Primers based HPV multiplex test, with clinical evaluations expected to begin early next year.
Manufacturing Capacity Expansion
Expansion of oligo synthesis facility in India nearing completion, with inauguration planned in early December, aiming to increase manufacturing capacity for the Co-Dx PCR platform.
---
CODX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CODX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $1.18 | $1.14 | -3.39% |
| Aug 08, 2024 | $1.02 | $1.12 | +9.80% |
| May 09, 2024 | $1.23 | $1.11 | -9.76% |
| Mar 14, 2024 | $1.19 | $1.07 | -10.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Co-Diagnostics Inc (CODX) report earnings?
Co-Diagnostics Inc (CODX) is schdueled to report earning on Apr 08, 2025, TBA Not Confirmed.
What is Co-Diagnostics Inc (CODX) earnings time?
Co-Diagnostics Inc (CODX) earnings time is at Apr 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CODX EPS forecast?
CODX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.34.
---